Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs.

Rigamonti AE, Cella SG, Marazzi N, Müller EE

Metabolism: clinical and experimental1 Feb 1999Cited by 3 (Europe PMC)

PMID10024078DOI10.1016/s0026-0495(99)90030-6PepBankPUB-10024078

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

01AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In young beagle dogs, the NO donor erythrityl tetranitrate potentiated GH secretion stimulated by hexarelin.
In plain wordsIn young dogs, a nitric oxide donor increased the growth hormone release caused by hexarelin.
Peptide
Hexarelin
Outcome
IncreaseHexarelin-stimulated GH secretion with NO donor in young dogs
Study
dogn = 8
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC(0-90)
878.5 ng x mL(-1) x h
hexarelin alone, young
GH AUC(0-90)
1994.04 ng x mL(-1) x h
hexarelin with NO donor, young
Source sentences
Summary
Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P <…
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407801
02AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In young beagle dogs, the NO synthase inhibitor L-NAME suppressed GH release induced by hexarelin.
In plain wordsIn young dogs, a nitric oxide synthase blocker lowered the growth hormone release caused by hexarelin.
Peptide
Hexarelin
Outcome
DecreaseHexarelin-induced GH release with L-NAME in young dogs
Study
dogn = 8
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
1367.68 ng x mL(-1) x h
hexarelin alone, young
GH AUC
411.12 ng x mL(-1) x h
hexarelin with L-NAME, young
Source sentences
Summary
L-NAME (5 mg x kg(-1) x 2 i.v.) suppressed GH release induced by the peptide in young dogs (1,367.68 +/- 251.87 v 411.12 +/- 68.49 ng x mL(-1) x h, P < .01)
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407803
03AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In young beagle dogs, indomethacin abolished the NO-donor potentiation of the GH response to hexarelin.
In plain wordsIn young dogs, indomethacin removed the boost that a nitric oxide donor gave to the growth hormone response to hexarelin.
Peptide
Hexarelin
Outcome
DecreaseNO-donor potentiation of hexarelin GH response with indomethacin in young dogs
Study
dogn = 8
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
1627.25 ng x mL(-1) x h
hexarelin with NO donor, young
GH AUC
1163.37 ng x mL(-1) x h
with indomethacin, young
Source sentences
Summary
Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05)
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407806
04AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In old beagle dogs, the NO donor erythrityl tetranitrate potentiated GH secretion stimulated by hexarelin.
In plain wordsIn old dogs, a nitric oxide donor increased the growth hormone release caused by hexarelin.
Peptide
Hexarelin
Outcome
IncreaseHexarelin-stimulated GH secretion with NO donor in old dogs
Study
dogn = 5
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC(0-90)
314.82 ng x mL(-1) x h
hexarelin alone, old
GH AUC(0-90)
1314.12 ng x mL(-1) x h
hexarelin with NO donor, old
Source sentences
Summary
Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P <…
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407802
05AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In old beagle dogs, the NO synthase inhibitor L-NAME potentiated GH release induced by hexarelin.
In plain wordsIn old dogs, a nitric oxide synthase blocker increased the growth hormone release caused by hexarelin.
Peptide
Hexarelin
Outcome
IncreaseHexarelin-induced GH release with L-NAME in old dogs
Study
dogn = 5
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
314.73 ng x mL(-1) x h
hexarelin alone, old
GH AUC
1103.97 ng x mL(-1) x h
hexarelin with L-NAME, old
Source sentences
Summary
L-NAME (5 mg x kg(-1) x 2 i.v.) suppressed GH release induced by the peptide in young dogs (1,367.68 +/- 251.87 v 411.12 +/- 68.49 ng x mL(-1) x h, P < .01), but potentiated it in old dogs (314.73 +/- 117.10 v 1,103.97 +/- 374.11 ng x mL(-1) x h, P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407804
06AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In old beagle dogs, indomethacin abolished the NO-donor potentiation of the GH response to hexarelin.
In plain wordsIn old dogs, indomethacin removed the boost that a nitric oxide donor gave to the growth hormone response to hexarelin.
Peptide
Hexarelin
Outcome
DecreaseNO-donor potentiation of hexarelin GH response with indomethacin in old dogs
Study
dogn = 5
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
1061.47 ng x mL(-1) x h
hexarelin with NO donor, old
GH AUC
365.69 ng x mL(-1) x h
with indomethacin, old
Source sentences
Summary
Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin
2 context sentences(design, population, supporting numbers)
Summary · context
and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407807
07AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In young and old beagle dogs, the inactive compound D-NAME did not affect the GH response to hexarelin.
In plain wordsIn young and old dogs, an inactive control compound did not change the growth hormone response to hexarelin.
Peptide
Hexarelin
Outcome
No significant changeHexarelin-induced GH release with D-NAME
Study
dogn: not reported in source
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
D-NAME (5 mg x kg(-1) x 2 i.v.) did not affect the GH response to Hexarelin in either young (1,328.68 +/- 433.54 ng x mL(-1) x h) or aged (342.32 +/- 84.82 ng x mL(-1) x h) dogs.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407805
08AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome
In young and old beagle dogs, indomethacin did not affect the plasma GH peak evoked by hexarelin alone.
In plain wordsIn young and old dogs, indomethacin did not change the growth hormone peak caused by hexarelin alone.
Peptide
Hexarelin
Outcome
No significant changeHexarelin-evoked plasma GH peak with indomethacin alone
Study
dogn: not reported in source
young and old beagle dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH AUC
786.04 ng x mL(-1) x h
hexarelin alone, young
GH AUC
960.04 ng x mL(-1) x h
hexarelin with indomethacin, young
GH AUC
474.55 ng x mL(-1) x h
hexarelin alone, old
GH AUC
490.82 ng x mL(-1) x h
hexarelin with indomethacin, old
Source sentences
Summary
without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1002407808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.